Azitra, Inc. Announces Cancellation of 2026 Special Meeting of Stockholders

Core Viewpoint - Azitra, Inc. has canceled its special meeting of stockholders originally scheduled for February 6, 2026, due to a lack of quorum, with the meeting now adjourned until March 6, 2026 [1] Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology [1] - The company's lead program, ATR-12, targets Netherton syndrome, a rare chronic skin disease with no approved treatment options, and includes a Phase 1b clinical trial in adult patients [1] - Azitra's ATR-04 program addresses EGFR inhibitor-associated rash, impacting approximately 150,000 people in the U.S., and has received Fast Track designation from the FDA [1] Technology and Development - Azitra's programs are developed from a proprietary platform of engineered proteins and topical live biotherapeutic products, which includes a microbial library of around 1,500 bacterial strains [1] - The platform is enhanced by artificial intelligence and machine learning technology to analyze and predict drug-like molecules from the microbial library [1]